Dexcom, Inc. ( DXCM ) shares are trading higher premarket on Friday after the company reported its fourth-quarter results after Thursday’s closing bell. 

Revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion. U.S. revenue rose by 4%, while international revenue rose by 17% on a reported basis and 19% on an organic basis.

Adjusted gross profit declined to $661.2 million from $663.8 million in the same quarter a year ago, and the corresponding margin shrank to 59.4% from 64.2%.

Adjusted operating income declined to $209.5 million from $242.7 million a year ago quarter, with margin contracted 470 basis points Y/Y to 18.8%.

Adjusted EPS of 45 cents missed the analyst consensus estimate of 50 cents. 

As of December 31, 2024, Dexcom ( DXCM ) had $2.58 billion in cash, cash equivalents and marketable securities, while its revolving credit facility remains undrawn.

Outlook: Dexcom ( DXCM ) reaffirmed its FY25 guidance for revenue of $4.60 billion (vs. cons. of $4.61 billion), adjusted gross profit margin of around 64%–65%, and adjusted operating margin of 21%.

The company sees adjusted EBITDA margin of approximately 30%.

Kevin Sayer, Dexcom’s chairman, president and CEO, said, “In 2024, we implemented our largest US commercial sales force expansion, had two major product launches with Dexcom One+ and Stelo and submitted our G7 15-day product to the FDA.” 

“As we enter 2025, we look forward to building on these investments as we unlock the next wave of access to Dexcom CGM globally.”

Investors can gain exposure to the stock via First Trust Nasdaq Lux Digital Health Solutions ETF and Spinnaker ETF Series Langar Global HealthTech ETF .

Price Action: DexCom ( DXCM ) shares are up 2.87% at $86.50 premarket at the last check Friday.

Read Also: 

If You Invested $100 In Bitcoin Last Valentine’s Day, Today It’d Be Worth More Than What An Average American Spends On Their Significant Other On The Day Of Love

Image via Shutterstock.